Igor V. Zverkov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Igor V. Zverkov has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Oleg N. Minushkin
Central State Medical Academy of Department for Presidential Affairs of the Russian Federation
9 shared publications - Leonid V. Maslovskii
Central State Medical Academy of Department for Presidential Affairs of the Russian Federation
7 shared publications - Tat'Jana L. Pilat
Research Institute of Occupational Medicine named after Academician N.F. Izmerov
4 shared publications - V. S. Inevatova
Aidiklinik LLC
4 shared publications - Yu. G. Kuznetsova
Central State Medical Academy of the Administration of the President of the Russian Federation
3 shared publications - A. E. Evsikov
Central State Medical Academy of Department for Presidential Affairs of the Russian Federation
2 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (8) , 662-669
Rome Criteria for irritable bowel syndrome, fifth revision: Key updates. A review
The Rome V Criteria, published in 2026, updates the scientific and clinical understanding of irritable bowel syndrome (IBS). It redefines IBS from a “functional disorder” to a “gut-brain interaction disorder,” emphasizing biological underpinnings. Recognized pathophysiological mechanisms include impaired motility, alterations in the microbiota and its metabolites, immune dysregulation, serotonin modulation, increased intestinal permeability, visceral hypersensitivity, and bile acid malabsorption. The updated criteria define IBS as recurrent abdominal pain and/or discomfort associated with changes in bowel habits, such as constipation, diarrhea, or a mixed pattern, with symptoms present for at least six months prior to diagnosis and persisting during the preceding three months. Notable updates include the reintroduction of “abdominal discomfort,” a reduced pain frequency threshold of at least three days per week, clarification that pain or discomfort should not be constant, and an auxiliary criterion specifying that pain or discomfort should not be exclusively related to menstruation. IBS is now classified into four primary subtypes based on predominant stool patterns, as determined by the Bristol Stool Form Scale: IBS with constipation, IBS with diarrhea, IBS with mixed bowel habits, and IBS with unclassified bowel habits. Diagnosis is based on typical symptoms in the absence of alarm features, and IBS is no longer considered a diagnosis of exclusion. The revised diagnostic algorithm involves sequential clinical assessment, targeted use of a limited set of laboratory and instrumental tests, and explicit criteria for further evaluation. The Rome V Criteria also recommend a stepwise approach to IBS therapy, including lifestyle and dietary modifications, pharmacological management of predominant symptoms, and behavioral interventions targeting brain-gut axis interactions.
- 9 September 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (8) , 662-669
Open AccessRome Criteria for irritable bowel syndrome, fifth revision: Key updates. A review
The Rome V Criteria, published in 2026, updates the scientific and clinical understanding of irritable bowel syndrome (IBS). It redefines IBS from a “functional disorder” to a “gut-brain interaction disorder,” emphasizing biological underpinnings. Recognized pathophysiological mechanisms include impaired motility, alterations in the microbiota and its metabolites, immune dysregulation, serotonin modulation, increased intestinal permeability, visceral hypersensitivity, and bile acid malabsorption. The updated criteria define IBS as recurrent abdominal pain and/or discomfort associated with changes in bowel habits, such as constipation, diarrhea, or a mixed pattern, with symptoms present for at least six months prior to diagnosis and persisting during the preceding three months. Notable updates include the reintroduction of “abdominal discomfort,” a reduced pain frequency threshold of at least three days per week, clarification that pain or discomfort should not be constant, and an auxiliary criterion specifying that pain or discomfort should not be exclusively related to menstruation. IBS is now classified into four primary subtypes based on predominant stool patterns, as determined by the Bristol Stool Form Scale: IBS with constipation, IBS with diarrhea, IBS with mixed bowel habits, and IBS with unclassified bowel habits. Diagnosis is based on typical symptoms in the absence of alarm features, and IBS is no longer considered a diagnosis of exclusion. The revised diagnostic algorithm involves sequential clinical assessment, targeted use of a limited set of laboratory and instrumental tests, and explicit criteria for further evaluation. The Rome V Criteria also recommend a stepwise approach to IBS therapy, including lifestyle and dietary modifications, pharmacological management of predominant symptoms, and behavioral interventions targeting brain-gut axis interactions.
- 27 January 2026
- Published by Alfmed LLC in Medical alphabet
- Vol. 1 (34)
The interrelationship between the exocrine and endocrine functions of the pancreas in health and disease
This article examines the theoretical aspects of the interaction between the exocrine and endocrine parts of the pancreas (P), as well as various pathologies illustrating these processes. The diseases covered include chronic pancreatitis (CP), acute pancreatitis (AP), diabetes mellitus (DM), pancreatic steatosis, and several others. Data on the prevalence of DM in various pancreatic pathologies and the incidence of exocrine pancreatic insufficiency (EPI) in DM are provided. Risk factors for DM in pancreatic pathology are presented. The mechanisms of pathogenesis of these conditions are discussed, and the presented concepts are supported by experimental data. Additionally, several potential therapeutic interventions that may improve treatment efficacy in these conditions are discussed.
- 27 January 2026
- Published by Alfmed LLC in Medical alphabet
- Vol. 1 (34)
The interrelationship between the exocrine and endocrine functions of the pancreas in health and disease
This article examines the theoretical aspects of the interaction between the exocrine and endocrine parts of the pancreas (P), as well as various pathologies illustrating these processes. The diseases covered include chronic pancreatitis (CP), acute pancreatitis (AP), diabetes mellitus (DM), pancreatic steatosis, and several others. Data on the prevalence of DM in various pancreatic pathologies and the incidence of exocrine pancreatic insufficiency (EPI) in DM are provided. Risk factors for DM in pancreatic pathology are presented. The mechanisms of pathogenesis of these conditions are discussed, and the presented concepts are supported by experimental data. Additionally, several potential therapeutic interventions that may improve treatment efficacy in these conditions are discussed.
- 22 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 64-73
Effectiveness of synbiotic biocomplexes in correction of gut microbiocenosis disorders
The state of the gut microbiota largely determines the course of pathological processes in the human body. Currently, there is no doubt about the role of dysbiosis in the development and progression of many disorders, including intestinal infections, IBS, IBD, SIBO, diverticular disease, celiac disease, cancer, food intolerance, allergies, liver and pancreatic diseases, obesity, diabetes, metabolic syndrome, hematological, cardiological, genitourinary, rheumatological, neurological and neuropsychiatric. The development of tools that correct the imbalance of the gut microbiota is one of the most promising areas of the modern science. Methods for diagnosing disorders of the gut microbiota are also being improved. The importance and expediency of including agents that modulate the state of the gut microbiota in the complex therapy of many diseases is confirmed by numerous foreign and domestic studies. The evolution of probiotic products has progressed from single-strain formulations containing one type of microorganism to modern multi-strain synbiotic complexes that combine probiotics and prebiotics. The first generations of probiotics were primarily aimed at replenishing beneficial bacteria, whereas contemporary biocomplexes exert multi-level effects – they regulate the composition and activity of the gut microbiocenosis, promote the synthesis of necessary bacterial metabolites, improve intestinal barrier function, and modulate the immune response. This review article is devoted to evaluating the effectiveness of synbiotic biocomplexes Normoflorin L, B, and Д in the correction of gut microbiocenosis disorders in antibacterial therapy, functional bowel diseases, inflammatory bowel diseases, chronic pancreatitis, celiac disease, metabolic disorders and obesity, diseases of the ENT organs, dermatological and gynecological diseases.
- 22 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 64-73
Effectiveness of synbiotic biocomplexes in correction of gut microbiocenosis disorders
The state of the gut microbiota largely determines the course of pathological processes in the human body. Currently, there is no doubt about the role of dysbiosis in the development and progression of many disorders, including intestinal infections, IBS, IBD, SIBO, diverticular disease, celiac disease, cancer, food intolerance, allergies, liver and pancreatic diseases, obesity, diabetes, metabolic syndrome, hematological, cardiological, genitourinary, rheumatological, neurological and neuropsychiatric. The development of tools that correct the imbalance of the gut microbiota is one of the most promising areas of the modern science. Methods for diagnosing disorders of the gut microbiota are also being improved. The importance and expediency of including agents that modulate the state of the gut microbiota in the complex therapy of many diseases is confirmed by numerous foreign and domestic studies. The evolution of probiotic products has progressed from single-strain formulations containing one type of microorganism to modern multi-strain synbiotic complexes that combine probiotics and prebiotics. The first generations of probiotics were primarily aimed at replenishing beneficial bacteria, whereas contemporary biocomplexes exert multi-level effects – they regulate the composition and activity of the gut microbiocenosis, promote the synthesis of necessary bacterial metabolites, improve intestinal barrier function, and modulate the immune response. This review article is devoted to evaluating the effectiveness of synbiotic biocomplexes Normoflorin L, B, and Д in the correction of gut microbiocenosis disorders in antibacterial therapy, functional bowel diseases, inflammatory bowel diseases, chronic pancreatitis, celiac disease, metabolic disorders and obesity, diseases of the ENT organs, dermatological and gynecological diseases.
- Open Access
- 17 October 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 42-47
Remote results of successful eradication Helicobacter pylori of patients with gastric ulcer (5-year follow-up)
Introduction . The Maastricht VI international guidelines define the most effective methods for diagnosing and treating H. pylori -associated peptic ulcer disease (PUD). Less attention has been paid to the subsequent course of PUD after successful eradication. Aim . To evaluate the impact of successful H. pylori eradication on the subsequent course of gastric ulcer disease (GUD). Materials and methods . Twenty patients with PUD after successful H. pylori eradication with a triple drug combination underwent annual EGDS for 5 years, including H. pylori biopsies, endoscopic pH monitoring, clinical dynamics, and blood gastrin and somatostatin levels. Results . Over a 5-year observation period, disease recurrences were detected: by clinical manifestations – in 50% of cases (in 83% of cases, relapses were low-symptom or asymptomatic), by EGDS – in 60% of cases (of which ulcers were recorded in 15% of cases and gastric erosions in 45%). Recurrence of H. pylori infection was recorded in 45% of patients (of which 15% – with gastric ulcers and 30% – with gastric erosions), and in 15% of patients, the cause of gastric erosions was the use of NSAIDs; it was accompanied by weak to moderate degrees of H. pylori contamination and gastrointestinal tract inflammation. Conclusion . A 5-year follow-up of PUD after successful eradication showed that H. pylori recurrence occurred in 45% of cases, with changes in the course of PUD. Benign (low-symptom and asymptomatic) recurrence was predominant, accompanied by mild to moderate H. pylori contamination and GM inflammation.
- 17 October 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 42-47
Open AccessRemote results of successful eradication Helicobacter pylori of patients with gastric ulcer (5-year follow-up)
Introduction . The Maastricht VI international guidelines define the most effective methods for diagnosing and treating H. pylori -associated peptic ulcer disease (PUD). Less attention has been paid to the subsequent course of PUD after successful eradication. Aim . To evaluate the impact of successful H. pylori eradication on the subsequent course of gastric ulcer disease (GUD). Materials and methods . Twenty patients with PUD after successful H. pylori eradication with a triple drug combination underwent annual EGDS for 5 years, including H. pylori biopsies, endoscopic pH monitoring, clinical dynamics, and blood gastrin and somatostatin levels. Results . Over a 5-year observation period, disease recurrences were detected: by clinical manifestations – in 50% of cases (in 83% of cases, relapses were low-symptom or asymptomatic), by EGDS – in 60% of cases (of which ulcers were recorded in 15% of cases and gastric erosions in 45%). Recurrence of H. pylori infection was recorded in 45% of patients (of which 15% – with gastric ulcers and 30% – with gastric erosions), and in 15% of patients, the cause of gastric erosions was the use of NSAIDs; it was accompanied by weak to moderate degrees of H. pylori contamination and gastrointestinal tract inflammation. Conclusion . A 5-year follow-up of PUD after successful eradication showed that H. pylori recurrence occurred in 45% of cases, with changes in the course of PUD. Benign (low-symptom and asymptomatic) recurrence was predominant, accompanied by mild to moderate H. pylori contamination and GM inflammation.
- Open Access
- 20 January 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 177-185
The effectiveness of the introduction of dietary therapeutic foods in the eradication of Helicobacter pylori in patients with chronic gastritis
Introduction. In recent years, a high resistance of H. pylori infection to antibiotics has been recorded both worldwide and in the Russian Federation. This was the basis for introducing diets that increase the sensitivity of H. pylori to antibiotics into eradication schemes.Aim. To evaluate the effect of specialized therapeutic nutrition products LEOVIT GASTRO on the eradication of H. pylori.Materials and methods. Two study groups were formed: the main group – 22 patients and the control group – 20 patients. The groups were randomized from 42 patients suffering from chronic gastritis associated with H. pylori, by random sampling. To assess the tolerability of treatment, in particular, biochemical blood tests were studied.Results. Therapeutic nutrition provides a significant eradication effect against the background of antibiotic therapy. In 92% of patients, a complete absence of H. pylori contamination was detected, and in 8% of patients the degree of contamination was very weak, although initially it was pronounced, while in the control group, a complete absence of H. pylori contamination was detected in 80% of patients. Analysis of the use of specialized food products indicates the possibility of their use in diseases of the gastrointestinal tract associated with H. pylori, as they promote epithelization, healing of the mucosa, reduction and elimination of inflammation, pain, and discomfort in the gastrointestinal tract.Conclusion. Therapeutic dietary nutrition LEOVIT GASTRO is one of the important factors positively influencing the success rate of eradication treatment.
- 20 January 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 177-185
Open AccessThe effectiveness of the introduction of dietary therapeutic foods in the eradication of Helicobacter pylori in patients with chronic gastritis
Introduction. In recent years, a high resistance of H. pylori infection to antibiotics has been recorded both worldwide and in the Russian Federation. This was the basis for introducing diets that increase the sensitivity of H. pylori to antibiotics into eradication schemes.Aim. To evaluate the effect of specialized therapeutic nutrition products LEOVIT GASTRO on the eradication of H. pylori.Materials and methods. Two study groups were formed: the main group – 22 patients and the control group – 20 patients. The groups were randomized from 42 patients suffering from chronic gastritis associated with H. pylori, by random sampling. To assess the tolerability of treatment, in particular, biochemical blood tests were studied.Results. Therapeutic nutrition provides a significant eradication effect against the background of antibiotic therapy. In 92% of patients, a complete absence of H. pylori contamination was detected, and in 8% of patients the degree of contamination was very weak, although initially it was pronounced, while in the control group, a complete absence of H. pylori contamination was detected in 80% of patients. Analysis of the use of specialized food products indicates the possibility of their use in diseases of the gastrointestinal tract associated with H. pylori, as they promote epithelization, healing of the mucosa, reduction and elimination of inflammation, pain, and discomfort in the gastrointestinal tract.Conclusion. Therapeutic dietary nutrition LEOVIT GASTRO is one of the important factors positively influencing the success rate of eradication treatment.
- Open Access
- 25 May 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 8,p. 87-95
The effectiveness of specialized medical dietary food product in the complex therapy of patients with pancreatitis in the acute stage
Introduction. Dietary nutrition is a physiological therapeutic and prophylactic approach for chronic pancreatitis during an exacerbation. Given the acute reaction of patients to various foods, specialized dietary products designed specifically for this pathology are of great importance. Aim. Evaluation of the clinical efficacy, safety and tolerability of the use of specialized therapeutic nutrition – jelly “Pancreatic” in chronic pancreatitis in the acute stage. Materials and methods. 20 patients of the main group with pancreatitis, along with standard therapy, received a dietary food product twice a day. The dynamics of pain, dyspeptic syndromes and intestinal dysfunction syndrome was studied; dynamics of the ultrasound picture of the pancreas; intestinal motility according to carbolene test; safety and tolerability of therapy by registering side effects and assessing the quality of life according to the SF-36 questionnaire, assessing well-being according to the visual analogue scale, and the organoleptic properties of the medicinal product. The comparison group consisted of 20 patients who received only standard pharmacotherapy. Results. The use of a dietary therapeutic food product is accompanied by a significant decrease in the frequency of nausea, belching, heaviness and flatulence in patients of the main group. The terms of relief or reduction in the intensity of symptoms of bitterness, nausea, heaviness in the abdomen, feelings of rapid satiety, flatulence were significantly lower in the main group (5–8 days compared to the control group (10–14 days). A significant normalization of GGT and CRP levels was established in the main group, while in the comparison group there was only a decrease in CRP. The ongoing complex therapy was accompanied by an improvement in the ultrasound picture of the pancreas, potentiation of the effects of pharmacotherapy and a significant improvement in the quality of life of patients. Conclusions. The conducted studies have shown high efficiency, good tolerability and safety of the therapeutic product “Pancreatic jelly” in the treatment of patients with chronic pancreatitis. Kissel “Pancreas” is recommended by the authors for active use in patients with pancreatitis as a therapeutic diet.
- 25 May 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 8,p. 87-95
Open AccessThe effectiveness of specialized medical dietary food product in the complex therapy of patients with pancreatitis in the acute stage
Introduction. Dietary nutrition is a physiological therapeutic and prophylactic approach for chronic pancreatitis during an exacerbation. Given the acute reaction of patients to various foods, specialized dietary products designed specifically for this pathology are of great importance. Aim. Evaluation of the clinical efficacy, safety and tolerability of the use of specialized therapeutic nutrition – jelly “Pancreatic” in chronic pancreatitis in the acute stage. Materials and methods. 20 patients of the main group with pancreatitis, along with standard therapy, received a dietary food product twice a day. The dynamics of pain, dyspeptic syndromes and intestinal dysfunction syndrome was studied; dynamics of the ultrasound picture of the pancreas; intestinal motility according to carbolene test; safety and tolerability of therapy by registering side effects and assessing the quality of life according to the SF-36 questionnaire, assessing well-being according to the visual analogue scale, and the organoleptic properties of the medicinal product. The comparison group consisted of 20 patients who received only standard pharmacotherapy. Results. The use of a dietary therapeutic food product is accompanied by a significant decrease in the frequency of nausea, belching, heaviness and flatulence in patients of the main group. The terms of relief or reduction in the intensity of symptoms of bitterness, nausea, heaviness in the abdomen, feelings of rapid satiety, flatulence were significantly lower in the main group (5–8 days compared to the control group (10–14 days). A significant normalization of GGT and CRP levels was established in the main group, while in the comparison group there was only a decrease in CRP. The ongoing complex therapy was accompanied by an improvement in the ultrasound picture of the pancreas, potentiation of the effects of pharmacotherapy and a significant improvement in the quality of life of patients. Conclusions. The conducted studies have shown high efficiency, good tolerability and safety of the therapeutic product “Pancreatic jelly” in the treatment of patients with chronic pancreatitis. Kissel “Pancreas” is recommended by the authors for active use in patients with pancreatitis as a therapeutic diet.
- Open Access
- 5 May 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 6,p. 126-133
Modern therapeutic dietary foods in the complex therapy of chronic reflux gastritis, not associated with HP infection
Introduction. Dietary nutrition is one of the most important and physiological therapeutic and preventive approaches for chronic reflux gastritis (CRG), not associated with HP infection. Aim. To analyze the effectiveness and safety of the use of specialized therapeutic nutrition (produced by LEOVIT) in chronic reflux gastritis (CRG), not associated with HP infection, in the acute phase. Materials and methods. A comparative randomized study included 40 patients with CRG, not associated with HP infection, in the acute phase. During the one-month course, standard diet therapy was used in the control group (20 patients), and in the patients of the main group (20 patients), diet therapy was carried out using specialized dietary products. The dynamics of clinical manifestations, changes in esophagogastroduodenoscopy (EGDS), blood test parameters, and the severity of dysbiosis were studied. Statistical processing of the research results was carried out with the determination of the significance of the mean values using the Student’s t-test. Results. It was found that the studied specialized therapeutic nutrition (oatmeal porridge with herbs and flax seed, vegetable soup with herbs and oatmeal, gastric jelly LEOVIT) have pleasant organoleptic properties, do not cause intolerance and allergic manifestations, restore digestion, improve the state of intestinal microflora, improve the quality of life of patients. According to endoscopic studies in the esophagus of patients in the main group, compared with patients in the comparison group, “normal” mucosa was statistically significantly more common (95 vs. 60% of cases) and catarrhal esophagitis was less common (5 vs. 40% of cases). The number of patients with an admixture of bile in the lumen of the stomach in patients of the main group compared with patients of the control group was found significantly less frequently in 20% of cases versus 75% of cases. Conclusion. The investigated approach to diet therapy with the use of specialized therapeutic nutrition in CRG is completely safe and recommended by the authors for long-term use in patients with this pathology.
- 5 May 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 6,p. 126-133
Open AccessModern therapeutic dietary foods in the complex therapy of chronic reflux gastritis, not associated with HP infection
Introduction. Dietary nutrition is one of the most important and physiological therapeutic and preventive approaches for chronic reflux gastritis (CRG), not associated with HP infection. Aim. To analyze the effectiveness and safety of the use of specialized therapeutic nutrition (produced by LEOVIT) in chronic reflux gastritis (CRG), not associated with HP infection, in the acute phase. Materials and methods. A comparative randomized study included 40 patients with CRG, not associated with HP infection, in the acute phase. During the one-month course, standard diet therapy was used in the control group (20 patients), and in the patients of the main group (20 patients), diet therapy was carried out using specialized dietary products. The dynamics of clinical manifestations, changes in esophagogastroduodenoscopy (EGDS), blood test parameters, and the severity of dysbiosis were studied. Statistical processing of the research results was carried out with the determination of the significance of the mean values using the Student’s t-test. Results. It was found that the studied specialized therapeutic nutrition (oatmeal porridge with herbs and flax seed, vegetable soup with herbs and oatmeal, gastric jelly LEOVIT) have pleasant organoleptic properties, do not cause intolerance and allergic manifestations, restore digestion, improve the state of intestinal microflora, improve the quality of life of patients. According to endoscopic studies in the esophagus of patients in the main group, compared with patients in the comparison group, “normal” mucosa was statistically significantly more common (95 vs. 60% of cases) and catarrhal esophagitis was less common (5 vs. 40% of cases). The number of patients with an admixture of bile in the lumen of the stomach in patients of the main group compared with patients of the control group was found significantly less frequently in 20% of cases versus 75% of cases. Conclusion. The investigated approach to diet therapy with the use of specialized therapeutic nutrition in CRG is completely safe and recommended by the authors for long-term use in patients with this pathology.
- Open Access
- 5 October 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 46-61
Features of diet therapy for H. pylori associated diseases of the gastrointestinal tract
This review of the literature is devoted to the importance of nutritional support in the treatment and prevention of diseases of the gastrointestinal tract associated with Helicobacter pylori. Modern data on the biological properties of H. pylori and the mechanisms of colonization of the microorganism in the gastrointestinal mucosa are presented. Information is provided on the virulence factors and factors that promote adhesion, depolymerization and dissolution of protective mucus, damage and circulatory disorders of the gastrointestinal mucosa, secreted by H. pylori (lipopolysaccharides and proteins of the outer shell of the bacterium, enzymes – mucinase, protease, phospholipase, urease, VacA cytotoxin). The article pays special attention to the issues of diet therapy, the role of various foods and their components in the dietary correction of disorders in gastrointestinal diseases associated with H. pylori. The causes of nutritional disorders in patients with gastrointestinal diseases are described and a detailed description of food products and their biologically active components with anti-Helicobacter activity is given. A special section is devoted to the use and effectiveness of specialized dietary products for therapeutic and preventive nutrition of domestic production (LLC “Leovit nutria”) and the features of use in diseases of the gastrointestinal tract mediated by H. pylori. The authors provide information on the composition of dietary products, their anti-inflammatory, antioxidant, immunotropic and other activities that underlie clinical efficacy. The article provides detailed recommendations on the use of specialized dietary foods for this pathology.
- 5 October 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 46-61
Open AccessFeatures of diet therapy for H. pylori associated diseases of the gastrointestinal tract
This review of the literature is devoted to the importance of nutritional support in the treatment and prevention of diseases of the gastrointestinal tract associated with Helicobacter pylori. Modern data on the biological properties of H. pylori and the mechanisms of colonization of the microorganism in the gastrointestinal mucosa are presented. Information is provided on the virulence factors and factors that promote adhesion, depolymerization and dissolution of protective mucus, damage and circulatory disorders of the gastrointestinal mucosa, secreted by H. pylori (lipopolysaccharides and proteins of the outer shell of the bacterium, enzymes – mucinase, protease, phospholipase, urease, VacA cytotoxin). The article pays special attention to the issues of diet therapy, the role of various foods and their components in the dietary correction of disorders in gastrointestinal diseases associated with H. pylori. The causes of nutritional disorders in patients with gastrointestinal diseases are described and a detailed description of food products and their biologically active components with anti-Helicobacter activity is given. A special section is devoted to the use and effectiveness of specialized dietary products for therapeutic and preventive nutrition of domestic production (LLC “Leovit nutria”) and the features of use in diseases of the gastrointestinal tract mediated by H. pylori. The authors provide information on the composition of dietary products, their anti-inflammatory, antioxidant, immunotropic and other activities that underlie clinical efficacy. The article provides detailed recommendations on the use of specialized dietary foods for this pathology.
- Open Access
- 3 September 2020
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (8) , 18-23
Chronic gastrite: modern state of the problem
Aim. Тo evaluate the modern view on the problem of chronic gastritis and the effectiveness of the drug ursodexic acid (UHC) Grinterol in the treatment of patients with chronic antral reflux-gastritis (biliar). Materials and methods. The work provides modern ideas about chronic gastritis, the issues of etiology and pathogenesis are considered. Contemporary classifications and the attitude of the authors of the work to them are presented. Clinical studies were conducted in 50 patients with chronic antral reflux-gastritis biliary (32 women and 18 men) between the ages of 20 and 80 years (average age 50.3 to 8.0 years). The treatment uses the drug Grinterol in a daily dose of 12.5 mg/kg of body weight for 4 weeks. Results. Among patients with chronic antral gastritis isolated patients with reflux-gastritis biliary, the pathogenetic factor of which is the damaging property of aggressive bile acids. The main treatment for such patients are drugs UHC (in this study (this study uses Grinterol at a daily dose of 12.5 mg/kg of body weight); the duration of treatment is 4 years. The overall efficiency (according to endomorphological data) was 76%, according to clinical data 100%. Discussion. Critical consideration of the classifications used and proposed for consideration indicates that the time has come for the adoption of a new classification with the allocation of reflux-gastritis biliary. Treatment of this form of antral gastritis is effective with UDHC drugs. Conclusion. the selection of a form of antral reflux-gastritis biliar in a separate classification group is scientifically justified. The results suggest that for the treatment of patients with chronic biliary refluxdrugs of choice are drugs UDHC.
- 3 September 2020
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (8) , 18-23
Open AccessChronic gastrite: modern state of the problem
Aim. Тo evaluate the modern view on the problem of chronic gastritis and the effectiveness of the drug ursodexic acid (UHC) Grinterol in the treatment of patients with chronic antral reflux-gastritis (biliar). Materials and methods. The work provides modern ideas about chronic gastritis, the issues of etiology and pathogenesis are considered. Contemporary classifications and the attitude of the authors of the work to them are presented. Clinical studies were conducted in 50 patients with chronic antral reflux-gastritis biliary (32 women and 18 men) between the ages of 20 and 80 years (average age 50.3 to 8.0 years). The treatment uses the drug Grinterol in a daily dose of 12.5 mg/kg of body weight for 4 weeks. Results. Among patients with chronic antral gastritis isolated patients with reflux-gastritis biliary, the pathogenetic factor of which is the damaging property of aggressive bile acids. The main treatment for such patients are drugs UHC (in this study (this study uses Grinterol at a daily dose of 12.5 mg/kg of body weight); the duration of treatment is 4 years. The overall efficiency (according to endomorphological data) was 76%, according to clinical data 100%. Discussion. Critical consideration of the classifications used and proposed for consideration indicates that the time has come for the adoption of a new classification with the allocation of reflux-gastritis biliary. Treatment of this form of antral gastritis is effective with UDHC drugs. Conclusion. the selection of a form of antral reflux-gastritis biliar in a separate classification group is scientifically justified. The results suggest that for the treatment of patients with chronic biliary refluxdrugs of choice are drugs UDHC.